The
latest market report published by Credence Research, Inc. “Global Antibacterial
Drugs Market - Growth, Share, Opportunities, Pipeline Analysis, Competitive
Analysis, and Forecast, 2016 - 2022,” the antibacterial drugs market was valued
at USD 42,232.2 Mn in 2015, and is expected to reach USD 45,909.4 Mn by 2022,
expanding at a CAGR of 1.15% from 2016 to 2022.
Browse the full report Antibacterial
Drugs Market - Growth, Share, Opportunities, Competitive Analysis, and
Forecast, 2016 – 2022 report at http://www.credenceresearch.com/report/antibacterial-drugs-market
Market Insights
Antibacterial
drugs are derived from bacteria or molds or are synthesized de novo. These
drugs treat infectious diseases caused by gram positive, gram negative, aerobic
and anaerobic bacteria that cannot be treated by any other method unlike other
diseases. Antibacterial drugs have several mechanisms of action, including
inhibiting cell wall synthesis, increasing cell membrane permeability,
interfering with protein synthesis, nucleic acid metabolism, and other
metabolic processes. The alarming antibacterial-resistance crisis has
penetrated the awareness of clinicians, researchers, policymakers, governments
and the public at large.
The
key factors assisting the growth of antibacterial drugs market are mounting
prevalence of infectious diseases, government support, and increased research
and development activities. However, evolving drug-resistant species, launch of
generics, and upcoming patent expirations are anticipated to restrict the
growth of the global market through 2022. Globally, the rise in geriatric
population is also being considered as one of the key growth factors as it will
indirectly increase the demand for various antibacterial drugs. The demand for
antibacterial drugs will continue to rise mainly due to increased prevalence of
resistant species that demand development of innovative molecules.
Pipeline Analysis
The
phase III drugs included in the pipeline analysis are solithromycin (Cempra,
Inc.), VivaGel/ SPL7013 (Starpharma Holdings Limited), surotomycin (Merck &
Co.), MK-3415A (Merck & Co.) and others. According to market experts, these
upcoming drugs assure to provide enhanced efficacy, shorter onset of action and
fewer side effects as compared to the currently available antibacterial drugs.
Thus, future commercialization of these drugs during the forecast period 2016 –
2022 is anticipated to have a reflective impact on the growth of the overall
antibacterial drugs market.
Key Market Movements:
Asia
Pacific presently dominates the overall market and is also projected to
experience the fastest growth throughout the forecast period
The
rising incidence and prevalence of antibacterial drug resistance bacteria
strains such as Methicillin-resistant Staphylococcus aureus (MRSA)
Stringent
regulatory policies applied by FDA and other government agencies across the
world is expected to reduce the risk of infection outbreak in hospitals
Novel
and developed treatments in pipeline are expected to assist the overall market
growth of antibacterial drugs market
About Us:
Credence
Research is a worldwide market research and counseling firm that serves driving
organizations, governments, non legislative associations, and not-for-benefits.
We offer our customers some assistance with making enduring enhancements to
their execution and understand their most imperative objectives. Over almost a
century, we’ve manufactured a firm extraordinarily prepared to this task.
Media Contact
Name: Chris Smith (Global Sales
Manager)
Address:
105 N 1st ST #429, SAN JOSE, CA 95103 US
Ph: 1-800-361-8290
No comments:
Post a Comment